Efficacy of the kinase inhibitor CHZ868 against JAK2 rearrangements in pediatric acute lymphoblastic leukemia

Key Points

• To evaluate the effectiveness of the kinase inhibitor CHZ868 on JAK2 rearrangements in pediatric acute lymphoblastic leukemia.
• Evaluated the inhibitory effects of CHZ868 on JAK2 rearrangements.
• Assessed cellular responses to treatment in leukemia cell lines.
• Conducted assays to measure inhibition of cellular growth.
• CHZ868 exhibited significant inhibition of growth in JAK2-rearranged leukemia cells.
• The inhibitor demonstrated improved cellular response compared to untreated controls.
• Response varied based on the specific JAK2 rearrangements present.